WiQo · Non-injectable peeling · Professional insight
Both are non-injectable peeling treatments from WiQo, but they are built on different technology and solve different clinical problems. Here we go through the differences in formulation, depth of action and which patient each product is best suited for.
Powerful biorevitalising peel with 33 % TCA, hydrogen peroxide and kojic acid. Stimulates fibroblasts deep in the dermis — for patients with more pronounced skin concerns.
Patented combination of ATCA, homocysteic acid, citric acid and phytic acid. Acts in the epidermis and upper dermis — for radiance, texture and more even pores, with minimal discomfort.
33 % trichloroacetic acid (TCA) modulated by hydrogen peroxide, with 5 % kojic acid added. The TCA penetrates into the dermis and stimulates the fibroblasts directly, without damaging the epidermis or causing visible peeling.
A newly patented combination of 33 % Ammonium Trichloroacetate (ATCA — a TCA derivative) and 2 % homocysteic acid (HoA), with citric acid and phytic acid added for mild exfoliation and radiance. HoA is not found in any other cosmetic product on the market, and stimulates NMDA receptors in the skin for a milder, more superficial effect than PRX-T33.
| Property | PRX-T33 | PRX Plus |
| Active ingredients | TCA 33 % + H₂O₂ + kojic acid 5 % | ATCA 33 % + homocysteic acid 2 % + citric acid/phytic acid |
| Depth of action | Deep dermal stimulation | Epidermis and upper dermis |
| Suitable for | Signs of ageing, reduced skin tone, scarring, pronounced photoageing | More even skin tone, smaller pores, increased radiance, younger/sensitive skin |
| Treatment strength | Stronger, intensive regeneration | Milder, well suited to patients sceptical about injections |
| Product volume per treatment | 1,5–2 ml (face/neck) | 1–1,5 ml (face/neck) — lower consumption |
| Interval between treatments | Every 7 days | Every 14 days |
| Downtime | None | None |
| Packaging | 5 × 4 ml | 5 × 4 ml (up to 20 treatments) |
Recommended treatment protocol: 4 treatments every 14 days, a follow-up treatment after 45 days, a new course after 6 months.
Source: manufacturer/distributor-published measurement on 30 women (aged 24–67) over 2 weeks, based on instrumental skin analysis (Visia, Dermascope, Ultrasound L20 HD3). This is not an independent peer-reviewed clinical study — the figures are WiQo's own, published through official distributor channels.
Yes. PRX Plus is not intended to replace PRX-T33 — the two products are designed to complement each other. Many clinics offer both and choose the product based on the patient's skin condition, treatment goals and comfort level, or combine them in an overall treatment plan to address both deeper and more superficial skin concerns.
PRX-T33 is based on 33 % TCA, hydrogen peroxide and kojic acid, and provides powerful dermal stimulation suited to deeper skin concerns. PRX Plus uses a patented combination of 33 % Ammonium Trichloroacetate (ATCA) and 2 % homocysteic acid (HoA), together with citric acid and phytic acid, and acts more superficially in the epidermis and upper dermis, targeted at radiance, texture and pore size.
No. PRX Plus has been developed to complement PRX-T33, not to replace it. The two products address different clinical needs and can be used in the same clinic for different patient groups or combined within the same treatment plan.
PRX Plus is well suited to younger or more sensitive skin, patients who want a more even skin tone, less visible pores and increased radiance, as well as patients who are nervous about injections or more invasive methods.
PRX-T33 is ideal for patients with deeper skin concerns such as signs of ageing, reduced skin tone, scarring and more pronounced photoageing. The stronger dermal stimulation is suited to more intensive skin regeneration protocols.
No, both treatments have been developed without superficial peeling or visible downtime. The patient can normally return to daily activities immediately after treatment.
No. The figures come from a manufacturer/distributor-published measurement on 30 women (aged 24–67), based on instrumental skin analysis (Visia, Dermascope, Ultrasound L20 HD3). It is not an independent peer-reviewed clinical study, and the figures should be read with that in mind.
BC Nordic distributes the entire WiQo range to clinics in the Nordics, with fast delivery and professional support.
See the PRX range →